Kymera Therapeutics Sets 2026 Clinical Strategy and Milestones

The latest announcement is out from Kymera Therapeutics ( (KYMR) ).

On January 13, 2026, Kymera Therapeutics outlined its 2026 objectives and clinical strategy, highlighting progress and upcoming milestones across its oral immunology pipeline, including the STAT6 degrader KT-621 and the IRF5 degrader KT‑579. The company reported that in December 2025 KT-621 produced positive Phase 1b data in moderate to severe atopic dermatitis patients, showing deep STAT6 degradation, robust biomarker reductions and meaningful clinical improvements that were in line with or numerically exceeded four-week dupilumab data, and the asset received FDA Fast Track designation that same month. KT-621 is now in Phase 2b development, with the BROADEN2 trial in atopic dermatitis dosing since November 2025 and recently expanded to include adolescents, and the BREADTH Phase 2b trial in eosinophilic asthma initiated in January 2026, with both studies expected to deliver data in 2027. Kymera has completed IND-enabling studies for KT-579, which demonstrated strong efficacy and clean safety in preclinical lupus and rheumatoid arthritis models, and plans to start a first-in-human Phase 1 healthy volunteer trial in the first quarter of 2026 with data anticipated in the second half of 2026. Additional pipeline momentum comes from partnered programs such as the IRAK4 degrader KT-485/SAR447971 with Sanofi, expected to enter Phase 1 in 2026, and an oral CDK2 molecular glue oncology program under an exclusive option and license agreement with Gilead, while Kymera also plans to advance at least one new first-in-class oral immunology candidate toward IND this year, underscoring its ambition to reshape treatment standards and consolidate its position as a leading player in oral immunology therapeutics.

The most recent analyst rating on (KYMR) stock is a Buy with a $138.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Spark’s Take on KYMR Stock

According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.

Kymera Therapeutics’ overall stock score is primarily impacted by its poor financial performance, which is a significant concern. However, strong technical indicators and positive corporate events provide some optimism. The earnings call also suggests strategic progress, but high expenses and valuation concerns remain.

To see Spark’s full report on KYMR stock, click here.

More about Kymera Therapeutics

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of oral small molecule degrader medicines for immunological diseases. The company is building an industry-leading portfolio of oral immunology programs targeting high-value, previously undrugged or poorly addressed targets, with a market focus on common immuno-inflammatory conditions such as atopic dermatitis, asthma, COPD, autoimmune disorders and other Type 2 and immune-mediated diseases, supported by partnerships with Sanofi and Gilead and a cash position of approximately $1.6 billion providing runway into 2029.

Average Trading Volume: 956,622

Technical Sentiment Signal: Buy

Current Market Cap: $5.9B

Learn more about KYMR stock on TipRanks’ Stock Analysis page.